“Automated Radiosynthesis modules drive the production of radiotracer for PET and SPECT (Single-Photon Emission Computed Tomography) imaging in decentralized settings. These modules are user friendly, simple to set up, and offer scope of customized formulations of radiotracer for diagnostic and therapy administration, and hence their adoption will be increasing in near future.”
Automated Radiosynthesis Module Market was valued at $20 million in 2015, and is expected to reach $32 million by 2022, supported by a CAGR of 6.6%. Radiosynthesis modules are available as automated equipment for decentralized settings for the formulation and production of radiotracers. Majority of the radiotracers are manufactured in the centralized laboratories and radiopharmaceutical units. This scenario has few imitations such as it reduces the scope for customization of production of radiotracer and increases the time gap for the radiotracer to reach the end users. As radiotracers have limited half-life, its performance decreases when employed for diagnosis or therapy administration. Automated radiosynthesis modules are simple to set up and easy to use and offers the scope for customization of the radiotracers. This in turn drives the performance of the diagnostic and therapy monitoring activities for the end users.
Rise in incidence of chronic diseases and increase in adoption of PET/SPECT imaging fuel the automation of radiotracer production process. Further, the supply of these products is anticipated to become streamlined and effective, owing to the improved cGMP guideline from the FDA. Manufacturers are expected to gain additional income by diversifying their product offering to cater to the needs of new markets. Premium pricing is projected to remain a source of concern and limit the rate of adoption of these module; however, the availability of funds and grants from the government is expected to offset this constraint.
Increase in Adoption of Pet & Spect as Vital Diagnostic Tools
The global burden for chronic diseases is increasing worldwide at an alarming rate. To control this situation, the global healthcare industry focuses on early diagnosis of disease to provide prompt treatment. This will facilitate reducing the global burden of chronic diseases such as cardiovascular diseases, chronic obstructive pulmonary disorder, cancer, and others. Diagnostics tools such as PET and SPECT are adopted globally to reduce the rapidly increasing chronic diseases, which provide high-resolution quality imaging, simplifying the complex diagnosis process. This equipment uses PET radiopharmaceuticals with short lifetime radioactive isotopes that are manufactured using fully automated radiosynthesis process. The radiopharmaceuticals are incorporated in the PET/CT/SPECT scanners to improve the utility of tomographic imaging diagnostics methods that are available commercially.
High Cost is a Barrier for Adoption of Automated Radiosynthesis Module
The manual radiosynthesis module causes exposure to radiation, which can pose as a possible harm to the radiopharmacist. Thus, the new era nuclear medicines and manufacturers of radiolabeled compounds are keen on adoption of automated radiosynthesis module. The average cost of automated radiosynthesis module is more than $50,000. Although these modules provide high accuracy, the high cost of installation and servicing limits its growth in the commercial market. In spite of the fact that there has been a global mandate to use automated radiosynthesis module to reduce radiation exposure to the operator in the clinical setting, the cost pose to be a barrier. The high start-up cost is projected to prohibit the users from the adoption of automated radiosynthesis module, which will further limit the growth of the market at a global platform.